Abstract
Chemotherapy-induced nausea and vomiting (CINV) is a major problem for patients who use chemotherapy and can lower the quality of life for many cancer patients. If the patient is continuing chemotherapy treatment, then the patient can be certain to experience CINV. Current CINV prevention strategies primarily use 5-hydroxytryptamine-3 receptor antagonists (5HT3-RAs), dexamethasone, and/or neurokinin-1 receptor antagonists (NK-1 RAs). However, these preventive therapies have not been fully implemented, especially the use of NK-1 RAs because of the high cost. In addition, a standard therapy for CINV prevention is still not effective in controlling CINV symptoms. One alternative CINV preventive therapy option is to use olanzapine. It is an antipsychotic drug that can be used as a preventive therapy for CINV off-label. The purpose of this study is to explain the utilization of olanzapine as alternative choice of antiemetic therapy in preventing CINV.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Advanced Multidisciplinary
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
